The trial enrolled 32 adolescents aged 12 to 18 who met DSM-5-TR criteria for depression, anxiety, or somatic symptom disorder, drawn from 155 screened at a single public primary care facility in Nairobi. The clinical picture was sobering: major depressive disorder dominated the sample, and the largest subgroup presented with severe depression accompanied by suicidal ideation. Participants, whose average age was about 15.6 years and who were evenly split by gender, were randomized one-to-one between the Ushirikiano model and an enhanced version of standard care that included a single group session on peer pressure, substance use, and school challenges. The researchers were explicit that the study was a pilot, powered for feasibility rather than definitive efficacy, and that no formal effect sizes or confidence intervals were computed.

The intervention itself is a study in pragmatic compression. Standard Interpersonal Psychotherapy for Adolescents, developed by Laura Mufson in the 1990s, typically involves 12 weekly individual sessions with a specialist. The Ushirikiano model condenses this into one individual pre-group session followed by four weekly 90-minute group meetings, guided by the World Health Organization’s group IPT manual, which outlines how an eight-session format can be adapted to a brief four-session structure. The first session combines assessment, formulation, and initial intervention; the middle two sessions actively address problem areas; and the final session consolidates gains and closes. The group format, the researchers argue, adds peer support, reduces stigma, and improves engagement, while the brevity boosts feasibility and retention among adolescents.

Delivery rested entirely on non-specialists. Seven community health promoters, along with a social worker, two psychologists, and two IPT supervisors, carried the intervention, receiving blended virtual and in-person training with ongoing supervision. Fidelity was monitored with the WHO Group IPT Task Checklist, and the results showed a clear supervision-driven learning curve: 88 percent of competencies were rated satisfactory or superior, and previously trained facilitators consistently outperformed newly trained ones, particularly in pre-group sessions. Skills requiring deeper clinical judgment, such as emotional exploration and case formulation, initially lagged but improved steadily as supervisors observed sessions and debriefed facilitators afterward.

The researchers framed their evaluation of acceptability and feasibility through the COM-B model, which analyzes behavior as the interaction of capability, opportunity, and motivation. On the capability front, the transformation was visible on both sides of the group room. Adolescents who initially struggled to name their feelings or connect mood to relationships progressively learned to link emotional states to interpersonal events, express emotions, and practice communication strategies through role-plays and problem-solving exercises. One participant described the relief of the group format directly: initially anxious about sharing in a group, they realized after the first session that many peers were struggling similarly, which gave them courage to participate. Facilitators, meanwhile, moved from confusion about basic tools, with one admitting she initially thought the PHQ-9 depression questionnaire was a medical procedure, to confident ownership of the sessions.

Opportunity proved equally decisive. Sessions were embedded in an existing primary care facility without disrupting clinic operations, scheduled on quieter weekday afternoons and Saturday mornings during school holidays to maximize attendance. The familiar setting helped both adolescents and facilitators, who could coordinate referrals and flag concerns to colleagues without special arrangements. The social dimension of the group itself emerged as a therapeutic engine: by the second session, participants who had been reluctant to speak began opening up as they recognized their struggles in others. One participant said it was relieving to hear that other adolescents their age suffered similarly, and that learning from other participants really helped.

Motivation, the third COM-B pillar, was sustained by the intervention’s perceived relevance and by visible symptom improvement. Participants reported applying skills to real-world stressors, and the qualitative accounts are striking in their specificity. One adolescent described confronting his father about his drinking, after which their relationship improved and the drinking stopped. Another, who had experienced suicidal thoughts, reported never feeling suicidal again after the sessions and now hoping to become a doctor. A mother whose daughter had presented with severe depression and a recent suicide attempt, and who was one of only two participants prescribed fluoxetine alongside the therapy, said the intervention had opened her eyes and that she did not think her daughter would still be alive without it. Such accounts are illustrative of lived experience rather than proof of effectiveness, but they chart the human stakes behind the statistics.

The preliminary quantitative trends, though descriptive, point in a promising direction. Depressive symptoms appeared to decline faster in the intervention group, and at the two-month follow-up, all but one IPT-G-A participant had reached symptomatic remission, compared with only one in the control arm. Functional outcomes on the WHO Disability Assessment Schedule 2.0 favored the intervention across several domains, with gains maintained or still improving at follow-up rather than fading. Only two participants, both with severe depression, active suicidal ideation, and prior suicide attempts, received fluoxetine 20 milligrams daily, decided after consultation among a psychiatrist, psychologists, and IPT supervisors. Both used the medication for two months and reported feeling able to manage with the skills they had learned. The authors caution that with only two medicated participants, the apparent additive benefit of fluoxetine cannot be disentangled from the therapy and must be treated as hypothesis-generating.

The study situates itself within a growing body of evidence for task-shifted psychological care in East Africa and beyond. Group IPT delivered by lay providers substantially reduced depression in a landmark 2003 cluster-randomized trial in rural Uganda, and the WHO formally endorsed group IPT delivered by non-mental-health workers in 2019. In Kenya, the SMART-DAPPER trial in Kisumu tested non-specialist-delivered IPT and nurse-prescribed fluoxetine for adults with depression and PTSD, and earlier work showed group IPT was acceptable for depressed adolescent mothers living with HIV. Comparable approaches, including the Shamiri intervention in Kenyan schools, lay-counsellor problem-solving therapy in India, teacher-delivered group cognitive behavioral therapy in Nigeria, and the Youth Friendship Bench in Zimbabwe, collectively suggest that brief, non-specialist-delivered psychological care is feasible across low-resource settings, with group IPT-A one promising option among several.

The limitations are candidly acknowledged: a small sample, a single site, a short follow-up, no blinding, and no assessment of outcomes specific to anxiety or somatic symptom disorder, which will be addressed in the planned fully powered trial. Mixed-gender groups required deliberate facilitation, with younger, female, and anxious participants needing active encouragement early on, and placing siblings or relatives in the same group restricted disclosure for at least one participant, prompting a protocol for separating family members in future trials. The emotional toll on facilitators also surfaced, with one describing how the negativity from eight different people accumulated unnoticed, leading supervisors to build debriefing and self-care into the supervision structure. Still, the core finding stands: a four-session, community-delivered group therapy embedded in routine primary care kept every adolescent in treatment, and most emerged from severe depression into remission within two months. For a region where specialist mental health care remains scarce and suicide ranks among the leading causes of death for young people, a model that adolescents finish, and that community health workers can run, may be the most consequential result of all.

Subject of Research: Task-shifted group interpersonal psychotherapy for adolescent depression in Kenyan primary care

Article Title: Acceptability and feasibility of the Ushirikiano treatment model for Kenyan adolescents: a pilot randomized controlled trial

Article References: Ali, N. A., Mwavua, S. M., Yator, O., Kathono, J., Huizink, A. C., & Kumar, M. (2026). Acceptability and feasibility of the Ushirikiano treatment model for Kenyan adolescents: a pilot randomized controlled trial. Frontiers in Child and Adolescent Psychiatry, 5, Article 1890788. https://doi.org/10.3389/frcha.2026.1890788

Image Credits: AI Generated

DOI: 10.3389/frcha.2026.1890788

Keywords: adolescent mental health, depression, interpersonal psychotherapy, Kenya, community health workers, task-shifting, primary care, pilot randomized controlled trial, fluoxetine, WHO mhGAP, low- and middle-income countries, stepped care

The scale of the problem is staggering. More than 53 million people worldwide are now living with and beyond cancer, and an international meta-analysis of 9,311 individuals found that 39 percent experience moderate fear of recurrence while 19 percent experience severe, clinically significant levels. That translates to more than 30 million people affected globally. Those with severe fear endure persistent preoccupation and worry, hypervigilance to every physical sensation, and genuine functional impairment, alongside poorer mental health, reduced quality of life, and heavier use of healthcare services. Receiving help with this fear has been identified as the single greatest unmet supportive care need among people with cancer.

What makes this gap so frustrating is that the science already exists. Validated screening instruments such as the Fear of Cancer Recurrence Inventory and the brief FCR-4/7 scales can identify who is struggling, and tested treatments including ConquerFear, Fear of Recurrence Therapy, and the SWORD blended cognitive behavioural therapy program have demonstrated real efficacy. Yet these tools rarely reach patients. Documented barriers include limited clinician awareness, inadequate referral pathways, equity concerns, workforce capacity constraints, and the difficulty of applying manualised interventions in the messy reality of diverse clinics. In 2024, Canadian guidelines and a complementary Australian clinical pathway finally offered formal guidance, both advocating routine screening followed by assessment and triage to stepped care.

The Australian team had already established, through a Delphi consensus process with 94 participants, that 35 of 38 proposed pathway elements were considered optimal for patient outcomes. But optimality is not the same as feasibility, and feasibility is a known antecedent of successful implementation. In the new secondary analysis, participants rated each element on a five-point Likert scale and provided open-ended commentary on practical obstacles. The results exposed a striking tension between what is best for patients and what health services can actually deliver. Feasibility ratings ranged from just 49.4 percent for training all clinical staff to conduct screening, up to 90.1 percent for the expectation that all health professionals validate and normalise patients’ fears.

The pattern was consistent across the pathway. Elements of the stepped-care treatment component, which matches support intensity to fear severity, attracted the highest average feasibility ratings at 75.9 percent, while the supported self-management component for moderate fear scored lowest at 61.0 percent. Resource-intensive recommendations, particularly universal training and repeated screening or booster sessions, were consistently judged least achievable. The researchers then applied directed content analysis using the updated Consolidated Framework for Implementation Research, coding 410 relevant qualitative responses across the framework’s Innovation, Individuals, Inner Setting, and Outer Setting domains. Of these, 170 were classified as barriers, 154 as enablers, and 53 as neutral factors.

The Inner Setting, meaning the organisational context of care, generated the most barriers by far, with 91 compared to just 45 enablers. Work infrastructure concerns, cited 30 times, centred on workforce capacity and the scarcity of mental health specialists, especially in regional centres where even available clinicians face demand exceeding supply. Available resources drew 31 barrier codes, reflecting worries about funding, staffing, and the cost of universal or repeated care elements. Participants also flagged equity issues, including the absence of culturally appropriate measures and the near-total lack of psychology services in rural and remote areas. By contrast, the pathway’s adaptability was the most frequently cited enabler within the Innovation domain, mentioned 22 times, with clinicians emphasising the need to tailor delivery for geographically isolated patients.

Human factors cut both ways. Screening was seen as empowering, giving patients permission to raise fears they might otherwise suppress, and the pathway’s responsiveness to patient need drew 25 enabler codes. Clinicians broadly agreed that screening falls within most staff capabilities. Yet opportunity emerged as a serious constraint: time and workload pressures limit screening opportunities, oncologists in particular are stretched thin by competing medical demands, and some participants worried that two-step screening adds administrative burden and that stepped care risks double-handling patients. There were also calls for shared decision-making, with some arguing that oncologists should only provide recurrence risk information when patients actually want it, and that treatment decisions for severe fear should involve patients as genuine partners.

From these determinants, the team used the CFIR-ERIC matching tool to link each barrier and enabler to evidence-based strategies from the Expert Recommendations for Implementing Change taxonomy. The resulting strategy set is pragmatic rather than revolutionary. Educational meetings and tailored, modular training resources should build awareness and capability across different professional roles, with online modules sufficient for triage conversations and targeted training extending the reach of nurses and allied health staff into moderate-severity interventions. Preparing local champions to model and support the pathway was proposed to overcome limited clinician opportunity, while engaging patients and families in shared decision-making addresses varied recipient needs. At the organisational level, the recommendations call for building coalitions beyond cancer centres, securing dedicated implementation funding, and aligning pathway components with existing workflows through process mapping.

Some of the most interesting implications concern workforce innovation. The authors suggest that coalitions of implementers could include trained lay workers, such as people affected by cancer themselves, who could assist with patient navigation, help identify those experiencing fear of recurrence, connect them with services, and provide emotional support. An umbrella review of patient navigation in cancer care found potential improvements in quality of life and psychological wellbeing, with no clear effectiveness difference between professional and lay navigators. Expanding primary care capacity could also relieve pressure on tertiary services, particularly for rural communities and First Nations, ethnic, and racial minority populations who may prefer community-based support. The researchers note that investment in fear-of-recurrence care may ultimately lower overall healthcare costs, strengthening the economic case for implementation.

The study has limitations worth noting. The sample, while multidisciplinary and experienced, was dominated by professionals in metropolitan public tertiary centres and lacked primary care clinicians, surgeons, palliative care specialists, patients, and cultural diversity, so findings may not generalise universally. Still, the authors argue that resource constraints appear common across settings, giving the strategies broader relevance. The bottom line is clear: a consensus-based, guideline-concordant pathway for one of cancer’s most pervasive psychological burdens now exists, and its success will depend less on the elegance of its design than on pragmatic local adaptation, prioritisation of high-impact elements, modular training, workflow integration, and system-level investment. The team’s next challenge is testing these strategies in real-world settings using hybrid effectiveness-implementation designs, so that the 30 million people living with fear of cancer’s return can finally access the care the science has long promised.

Subject of Research: Implementation of a clinical pathway for screening and stepped-care management of fear of cancer recurrence

Article Title: Designing for delivery: a Delphi study of feasibility-informed implementation strategies for a fear of cancer recurrence clinical pathway

Article References: Smith, B., Wu, V. S., Pearce, A., Liu, J., Shepherd, H. L., Shaw, J., Girgis, A., Garvey, G., Kirsten, L., Zakhary, I., Ee, C., Ewald, D., Miller, A., Smith, A., Virk, A. K., Gao, J., & Taylor, N. (2026). Designing for delivery: a Delphi study of feasibility-informed implementation strategies for a fear of cancer recurrence clinical pathway. Supportive Care in Cancer, 34(11), Article 1079. https://doi.org/10.1007/s00520-026-11275-9

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11275-9

Keywords: fear of cancer recurrence, cancer survivorship, clinical pathway, implementation science, Delphi study, stepped care, supportive care, CFIR, psychological interventions, health workforce, patient navigation, screening

The study was led by Marco Angrisani, senior economist at the USC Center for Economic and Social Research and associate professor (research) of economics at the USC Dornsife College of Letters, Arts and Sciences. Angrisani and his colleagues set out to answer a question that has troubled mental health researchers for decades: why do responses to large-scale societal stressors vary so dramatically from one person to the next? Their answer, drawn from one of the most extensive longitudinal datasets available, points to personality as a meaningful and measurable factor in shaping that heterogeneity. “There is a wide variety of mental health responses to large-scale societal stressors,” Angrisani said. “Our study shows that personality traits, and neuroticism in particular, play a role in shaping heterogeneous responses in a major crisis across individuals and could therefore inform better targeted interventions.”

The evidence base for these conclusions is unusually robust. The researchers followed 4,030 U.S. adults using data from the Understanding America Study, a nationally representative internet panel managed by the USC Center for Economic and Social Research. The analysis drew on more than 100,000 survey responses collected from 2019 through early 2024, a window that allowed the team to compare mental health before, during, and after the pandemic. That temporal span matters enormously. Cross-sectional studies conducted at a single point in time can show that distress was high during the pandemic, but they cannot reveal whether it rose, fell, or lingered afterward. By anchoring their measurements in pre-pandemic baselines and extending them well into the recovery period, the researchers could distinguish acute, transient distress from the kind of prolonged suffering that signals genuine vulnerability.

At the heart of the analysis were the so-called Big Five personality traits, the dominant framework in contemporary personality psychology. Neuroticism describes a tendency to experience worry, emotional sensitivity, and stronger reactions to stress or uncertainty. Extraversion captures the tendency to be outgoing, energetic, and motivated by social interaction. Openness reflects curiosity about new ideas and experiences and a willingness to consider change. Agreeableness denotes a tendency to be cooperative, trusting, and concerned about social harmony, while conscientiousness describes people who are organized, dependable, self-disciplined, and goal-oriented. Crucially, these characteristics exist on a continuum. Everyone possesses some degree of each trait, and a high or low score on any dimension does not constitute a disorder. The Big Five model is valued by researchers precisely because it reduces the enormous complexity of human temperament to five stable, measurable dimensions that can be tracked over time and correlated with real-world outcomes.

Mental distress in the study was measured with the PHQ-4, a brief validated questionnaire that assesses symptoms of anxiety and depression. A score of six or higher on the PHQ-4 indicates moderate-to-severe symptoms, although the instrument is a screening tool rather than a clinical diagnosis. Using this threshold, the researchers quantified how the probability of moderate or severe distress shifted across the pandemic for people at different points on the personality spectrum. The results were striking. Increases in the probability of moderate or severe distress were approximately 11 to 20 percentage points greater among participants who scored in the highest 25 percent for neuroticism compared with those in the lowest quarter. In practical terms, this means that highly neurotic individuals were dramatically more likely to cross the threshold into clinically significant distress as the crisis unfolded.

Just as important as the size of the effect was its persistence. The association between neuroticism and elevated distress held across young, middle-aged, and older adults, and it remained evident into the post-pandemic observation period. This durability is what distinguishes the finding from earlier work documenting short-lived spikes in anxiety during lockdowns. The pandemic has largely receded as an acute threat, yet the psychological shadow it cast appears to have lingered far longer for people high in neuroticism than for their more emotionally stable counterparts. For health systems still grappling with elevated demand for mental health services, that pattern suggests the pandemic’s toll was not merely an episode but, for a vulnerable segment of the population, a lasting shift.

The study also uncovered behavioral differences that may help explain the mechanism. Participants higher in neuroticism perceived greater health and financial risks during the crisis, adopted more protective behaviors, and reported exercising and relaxing less frequently while consuming more alcohol. These patterns sketch a coherent picture: people who react strongly to uncertainty tend to perceive danger more acutely, respond with heightened caution, and simultaneously withdraw from the very activities, such as exercise, relaxation, and moderate drinking habits, that buffer against psychological distress. Measurements of extraversion, openness, and agreeableness showed weaker or inconsistent associations with distress trajectories, while conscientiousness appeared modestly protective, particularly among adults aged 60 and older. That last finding hints that the self-discipline and structure characteristic of conscientious individuals may function as a psychological resource in older adults facing prolonged disruption.

The practical implications extend well beyond pandemic planning. The findings could help clinicians and emergency planners recognize who may need closer follow-up after disasters, public-health emergencies, or other prolonged disruptions. Public information campaigns could also be tested to ensure they inform people without unnecessarily increasing distress among those who are more vulnerable to it. Angrisani was careful to emphasize, however, that personality should be just one part of a broader risk assessment, considered alongside current symptoms, previous mental health conditions, and social circumstances, rather than serving as a label or an automatic trigger for treatment. Neuroticism is a risk factor, not a diagnosis, and it does not determine any individual’s mental health destiny. In the paper, the authors advocate for monitoring and stepped care: following people over time and offering treatments such as cognitive behavioral therapy or emotion-regulation training when significant, persistent symptoms emerge, rather than treating people solely because of a personality score.

Like all observational research, the study has limits that the authors acknowledge. It identifies associations and cannot prove that personality, especially neuroticism, caused the distress patterns observed. All personality and mental distress measures were self-reported, which introduces the possibility of reporting bias, and the findings may not generalize beyond the United States. Even so, the scale and duration of the dataset give the results considerable weight, and they point toward a concrete strategy for the future: crisis communication that emphasizes practical, controllable actions, combined with accessible mental health support, could help protect psychologically vulnerable groups when the next major disruption arrives. As climate events, geopolitical instability, and future pandemics test societies around the world, the USC-led study offers a deceptively simple insight with far-reaching consequences. The question of who will suffer most in a crisis may be partly answerable in advance, and answering it could mean the difference between reactive care and genuinely preventive support for the millions of people whose minds bear the longest scars of collective trauma.

Subject of Research: The influence of personality traits, particularly neuroticism, on the persistence of mental distress during and after the COVID-19 pandemic

Article Title: Personality traits influence level of lasting distress during a crisis, USC-led study finds

Article References: Personality traits influence level of lasting distress during a crisis, USC-led study finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neuroticism, personality traits, Big Five, mental distress, COVID-19 pandemic, anxiety, depression, PHQ-4, Understanding America Study, stepped care, observational study, USC

The letter arrives as a direct response to an updated meta-analysis of randomized controlled trials of acceptance and commitment therapy for insomnia, published earlier in the same journal by Barroso and colleagues. That meta-analysis pooled trial data to estimate how well ACT performs against control conditions and other active treatments, and its findings have been interpreted by some as support for expanding ACT’s footprint in behavioral sleep medicine. Saripudin and Saputri do not dispute the underlying data. Instead, they use the meta-analysis as a springboard to ask a more fundamental question: are current trials of ACT for insomnia designed well enough to tell us where the therapy genuinely helps, for whom, and at what point in a treatment pathway it should be deployed?

Acceptance and commitment therapy differs from standard CBT-I in a philosophically and mechanically important way. Rather than targeting sleep directly through stimulus control, sleep restriction, and cognitive restructuring of dysfunctional beliefs about sleep, ACT draws on relational frame theory and psychological flexibility research, a framework codified by Steven Hayes and colleagues in their foundational 2006 model of the approach. In the insomnia context, this means helping patients observe their sleep-related thoughts and anxieties without struggling against them, defusing from catastrophic predictions about the consequences of a bad night, and redirecting energy toward valued activities regardless of how sleep unfolds. The metacognitive model of insomnia developed by Ong, Ulmer, and Manber in 2012 provides the theoretical scaffolding here: insomnia is maintained not simply by poor sleep but by excessive monitoring of sleep, worry about sleep, and futile efforts to control a largely involuntary process.

The first methodological challenge highlighted by the letter concerns the heterogeneity of what actually gets called ACT in insomnia trials. Component network meta-analysis of CBT for chronic insomnia, such as the 2024 systematic review by Furukawa and colleagues in JAMA Psychiatry, has shown that the specific ingredients bundled inside a treatment package matter, and that different delivery formats produce different effect sizes. When one trial delivers pure acceptance and defusion exercises while another folds in sleep restriction, relaxation training, and psychoeducation under the ACT banner, the pooled estimate from a meta-analysis becomes difficult to interpret. Saripudin and Saputri argue that future trials must specify and measure the treatment components with the same rigor applied to pharmacological dosing, otherwise clinicians cannot know whether it is the acceptance processes or the borrowed behavioral elements driving observed improvements.

A second challenge involves the measurement of the very mechanisms ACT claims to target. If psychological flexibility, acceptance, and defusion are the active ingredients, then trials should track changes in these processes and demonstrate that they mediate sleep outcomes. Many existing studies measure only symptom endpoints such as insomnia severity or sleep-onset latency, leaving a black box between intervention and effect. Without mediation analyses and process measures, the field cannot distinguish a genuine mechanism-driven therapy from a repackaged relaxation intervention. The letter’s authors contend that this measurement gap is not a technical detail but the central scientific question, because it determines whether ACT is a distinct therapeutic modality for insomnia or simply a sympathetic framing of existing techniques.

The third pillar of the letter is the proposal to integrate ACT into a stepped-care architecture for insomnia. Stepped-care models allocate treatment intensity according to severity and prior response, beginning with low-intensity, widely accessible interventions and escalating only when needed. In such a system, ACT could occupy a strategically valuable position: for patients who refuse or fail sleep restriction, for those whose insomnia is entangled with chronic pain, anxiety, or depression, and for individuals whose primary problem is the struggle against sleep rather than sleep itself, acceptance-based approaches may be more acceptable and more effective than classic CBT-I protocols. Positioning ACT as either a first-line option for struggle-dominant presentations or a second step after CBT-I nonresponse is, in the authors’ view, a testable and clinically meaningful hypothesis that current trial designs have not yet addressed.

Underpinning this stepped-care argument is the often-overlooked issue of acceptability. Research on adherence to CBT-I, including the systematic review by Matthews and colleagues published in Sleep Medicine Reviews, has documented that many patients abandon sleep restriction partway through, and studies of patient perceptions toward insomnia treatments by Cheung and colleagues have shown that people frequently hold reservations about behavioral prescriptions that initially worsen sleep. Acceptability, the letter argues, should be treated as a formal outcome metric rather than an afterthought. Trials should systematically quantify tolerability, dropout attributable to treatment burden, patient-rated willingness to continue, and the match between treatment demands and patient preferences. If ACT’s chief comparative advantage is that patients will actually do it, then the field needs standardized instruments to demonstrate that advantage rather than relying on anecdote.

The implications of the letter extend beyond behavioral sleep medicine into health policy and service design. Insomnia affects a substantial share of adults, contributes to accidents, cardiovascular and metabolic disease, and psychiatric morbidity, and consumes enormous healthcare resources, yet access to trained CBT-I therapists remains scarce in most health systems. Digital and guided self-help formats have been proposed to close the access gap, and the component questions raised by Saripudin and Saputri apply with equal force here: if ACT is delivered through an app or a brief primary-care consultation, which elements survive the compression, and do the acceptance processes still engage? The authors suggest that acceptability metrics become a gating criterion in stepped-care algorithms, allowing services to route patients toward the least intensive treatment they will actually complete, which maximizes population-level benefit from limited clinician time.

None of this diminishes the significance of the updated meta-analysis that prompted the correspondence. Pooling randomized controlled trials is exactly the right starting point, and the finding that ACT produces measurable benefits for insomnia patients is noteworthy on its own terms. The letter’s contribution is to insist on intellectual honesty about what the pooled estimate can and cannot support. Effect sizes derived from heterogeneous packages, without mechanism data, without acceptability measurement, and without head-to-head comparisons at defined steps of a care pathway, justify curiosity rather than clinical rollout. The distinction matters because premature scaling of an incompletely characterized therapy risks repeating the access-versus-evidence tensions that have complicated other behavioral health rollouts.

What happens next will depend on whether trialists take up the design challenges laid out in the letter. The prescriptions are concrete: pre-register component definitions, include validated process measures of psychological flexibility and acceptance, conduct formal mediation analyses, report standardized acceptability outcomes, and embed ACT within stepped-care trials that compare explicit treatment sequences rather than isolated packages. If the field responds, the result could be a genuinely personalized behavioral sleep medicine, in which a patient whose insomnia is driven by nocturnal struggle is steered toward acceptance-based work while a patient with entrenched sleep-incompatible habits receives restriction-based CBT-I first. If the field does not respond, acceptance and commitment therapy risks remaining an attractive but under-specified option, championed by enthusiasts and underused by systems. Saripudin and Saputri’s letter is, in effect, a roadmap for turning promising pooled statistics into a defensible, patient-centered treatment strategy, and it arrives at a moment when demand for better insomnia care has never been higher.

Subject of Research: Optimizing acceptance and commitment therapy for insomnia through improved trial methodology, stepped-care integration, and acceptability measurement

Article Title: Optimizing the role of acceptance and commitment therapy for insomnia: methodological challenges, stepped-care integration, and acceptability metrics

Article References: Saripudin, M., & Saputri, H. (2026). Optimizing the role of acceptance and commitment therapy for insomnia: methodological challenges, stepped-care integration, and acceptability metrics. Journal of Clinical Sleep Medicine, 22(1), Article 160. https://doi.org/10.1007/s44470-026-00184-7

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00184-7

Keywords: acceptance and commitment therapy, insomnia, cognitive behavioral therapy for insomnia, stepped care, psychological flexibility, sleep medicine, meta-analysis, treatment acceptability, randomized controlled trials, behavioral sleep medicine, adherence, methodology